VC & Startups/Nov 21 edition/Reporting & analysis
FundingValuationsFounders

FundingRounds, leads & terms

Science Corp. raises $400M Series D for its PRIMA retinal implant, the largest U.S. venture round of the week

Science Corp., the neurotech startup founded by former Neuralink president Max Hodak, raised a $400M Series D led by Khosla Ventures to expand European sales of its PRIMA retinal implant, pursue U.S. approval and advance a biohybrid brain interface.

From the Crunchbase News article of November 20, 2026 and cited sources: Crunchbase ranked Science's $400M Series D as the largest U.S. round for Nov. 14–20, 2026. [1] [3] [9]

SOURCES[1] Crunchbase News: The Week's 10 Biggest Funding Rounds news.crunchbase.com[3] TechCrunch: Science Corporation's brain tech is worth $3.5B techcrunch.com[9] SiliconANGLE: Science Corp. raises $400M siliconangle.com

AI-assisted, not human-edited. Methodology Corrections Who owns this site

KEY FACTS
What happened
Crunchbase ranked Science's $400M Series D as the largest U.S. round for Nov. 14–20, 2026. [1] [3] [9]
Original source
Crunchbase News article, independent perspective
Brief by
AT Pulse research desk AI-assisted; publisher and contact on the desk page
When
November 20, 2026 article published
Evidence
10 sources across 10 sites

Reach: not measured yet

THE CORE IDEAS4 TAKEAWAYS
01

Crunchbase ranked Science's $400M Series D as the largest U.S. round for Nov. 14–20, 2026. The money will pay for PRIMA's European rollout, a planned U.S. launch through the FDA's Humanitarian Device Exemption pathway, and an experimental implant that pairs cultured neurons with a silicon chip. [1] [3] [9]

02

PRIMA already has clinical results and regulatory approval. In a multicenter trial published in NEJM, 26 of 32 patients with geographic atrophy who were assessed at 12 months had clinically meaningful gains in visual acuity, with an average gain of 25.5 letters on the standard eye chart. The device received its CE mark in July 2026 and went on sale first in Germany. [4] [5] [7] [8]

03

Science's rounds have grown quickly. A $230M Series C in March brought total funding to about $490M, and the new round came eight months later. The reported $3.5B valuation comes from a person familiar with the deal and has not been confirmed by the company. [6] [3]

04

AI deals filled the next spots in the weekly ranking: Model ML raised $250M from General Atlantic and QED, and Noeri raised $110M led by Menlo Ventures. Biotech company Galvanize Therapeutics raised $130M. [1]

WHY IT MATTERS

Peer-reviewed trial data and a CE mark put PRIMA on the market ahead of better-known brain-computer interface rivals.

Read the full assessment

That suggests investors will pay for neurotech with near-term regulatory paths, even in a week full of AI deals, though no revenue has been disclosed.

Executive brief

The biggest U.S. venture round of the week of Nov. 14–20, 2026 went to a sight-restoring retinal implant, not an AI lab. Science Corp., founded by former Neuralink president Max Hodak, raised a $400M Series D (Crunchbase News). The reported $3.5B valuation comes from a person familiar with the deal and has not been confirmed by the company (TechCrunch). The money pays for European rollout of the PRIMA implant, a planned U.S. launch, and Science's experimental "biohybrid" brain interface. AI deals came next on the list: Model ML ($250M) and Noeri ($110M).

What changed and event timeline

  1. PRIMA trial published in NEJM

    The PRIMAvera trial enrolled 38 patients with geographic atrophy (GA), late-stage dry age-related macular degeneration (AMD). Of the 32 assessed at 12 months, 26 had clinically meaningful gains in visual acuity (;).

  2. $230M Series C

    Existing investors Khosla, Lightspeed, Y Combinator, IQT and Quiet Capital put in $230M, taking total funding to about $490M. The CE mark and FDA applications were still pending at that point ().

  3. CE mark and European launch

    Notified body DEKRA certified PRIMA under the EU Medical Device Regulation, which allows sales in 30 European countries. Germany was the first market (;).

  4. $400M Series D announced

    Ackman Oxman Institute, Tenet Healthcare, 885 Capital, Y Combinator and PLC Neurotech also invested (;).

  5. Tops weekly rankings

    Crunchbase ranked Science first among U.S. rounds that week. Next came Model ML ($250M, General Atlantic and QED), Galvanize Therapeutics ($130M) and Noeri ($110M, Menlo Ventures) ().

Capabilities and access

  • PRIMA system: a subretinal photovoltaic implant with 378 pixels, each with its own electrode.
  • Italy, France and the U.K. are expected in the coming months.
  • Pipeline: Stargardt disease trials have started, and retinitis pigmentosa is also targeted (TechCrunch).
Read the full section
  • PRIMA system: a subretinal photovoltaic implant with 378 pixels, each with its own electrode. Glasses project near-infrared light onto the chip, which then stimulates the remaining retinal cells (SiliconANGLE).
  • Access: sold in Germany now. Italy, France and the U.K. are expected in the coming months. U.S. access is being sought through the FDA's Humanitarian Device Exemption (HDE) pathway, which Hodak told Bloomberg he hopes will happen "early next year" (as reported by SiliconANGLE).
  • Pipeline: Stargardt disease trials have started, and retinitis pigmentosa is also targeted (TechCrunch).

Technical analysis for researchers and developers

  • The near-infrared light carries both the image and the power, so the implant needs no external power link.
  • Evaluation: a multicenter trial (17 sites, five countries) with 12-month visual-acuity endpoints, published in a peer-reviewed journal (PubMed).
  • Biohybrid: an implant that combines cultured neurons with a silicon chip. No peer-reviewed data on it appears in the reviewed sources.
Read the full section
  • Architecture: PRIMA works without wires. The near-infrared light carries both the image and the power, so the implant needs no external power link. It replaces lost photoreceptors by stimulating the inner retinal neurons that remain.
  • Evaluation: a multicenter trial (17 sites, five countries) with 12-month visual-acuity endpoints, published in a peer-reviewed journal (PubMed). Mean improvement was 25.5 ETDRS letters (Ophthalmology Times). The ETDRS chart is the standard eye-chart test used in clinical trials.
  • Biohybrid: an implant that combines cultured neurons with a silicon chip. Animal testing is complete, and Science says it aims for first human trials within 16 months, led by Yale neurosurgeon Murat Günel (SiliconANGLE). No peer-reviewed data on it appears in the reviewed sources.

Claims and evidence

No revenue or implant-volume figures have been disclosed.

Read the full section
ClaimStatus
$400M Series DCompany-announced and reported independently by several outlets (TNW)
$3.5B post-money valuationFrom an unnamed source (TechCrunch); not company-confirmed or confirmed by any filing
Khosla ledReported by TechCrunch and SiliconANGLE; one roundup calls the lead investor unconfirmed (shattered.io)
Total raised over $900MCompany figure. The Series C total (~$490M) plus $400M comes to roughly $890M, a small unexplained gap
"First BCI with a CE mark to restore form vision"Company framing (TNW)

No revenue or implant-volume figures have been disclosed.

Context and prior work

Science was founded in 2021 by Hodak after his time at Neuralink (2016–2020) (TNW). Across the brain-computer interface (BCI) field, Science stands out because its first product is a retinal implant with a near-term regulatory path rather than a cortical implant. That is why it has a CE-marked product before its better-known rivals.

Read the full section

Science was founded in 2021 by Hodak after his time at Neuralink (2016–2020) (TNW). Across the brain-computer interface (BCI) field, Science stands out because its first product is a retinal implant with a near-term regulatory path rather than a cortical implant. That is why it has a CE-marked product before its better-known rivals. Its rounds have grown fast: $230M in March, then $400M eight months later (MedTech Dive).

Limitations, safety and contested findings

  • Atrophy: in the trial, the atrophic area grew by 8.5 mm² in implanted eyes versus 2.5 mm² in untreated eyes.
  • Scope: the evidence comes from 32 patients assessed at 12 months, all with GA.
  • U.S. approval: PRIMA still needs HDE clearance before it can be sold in the U.S.
Read the full section
  • Atrophy: in the trial, the atrophic area grew by 8.5 mm² in implanted eyes versus 2.5 mm² in untreated eyes. The investigators attributed this to the disease itself, not the implant (Retinal Physician).
  • Scope: the evidence comes from 32 patients assessed at 12 months, all with GA.
  • U.S. approval: PRIMA still needs HDE clearance before it can be sold in the U.S.
  • Conflicting roundup figures: Crunchbase lists Marrow Therapeutics at $120M, while another roundup reports $173M.

Business and practitioner implications

  • Investor mix: Tenet Healthcare, a hospital operator, is among the investors.
  • Regulatory sequencing: a CE mark first, then a narrow U.S. pathway (HDE), is a model other neurotech companies can learn from.
  • AI capital: in the same week, AI deals that Crunchbase tracked include Model ML (AI for finance), Noeri (enterprise AI) and BrightAI ($97M, physical AI).
Read the full section
  • Investor mix: Tenet Healthcare, a hospital operator, is among the investors. That points to interest in surgical delivery capacity, though its strategic role has not been disclosed.
  • Regulatory sequencing: a CE mark first, then a narrow U.S. pathway (HDE), is a model other neurotech companies can learn from.
  • AI capital: in the same week, AI deals that Crunchbase tracked include Model ML (AI for finance), Noeri (enterprise AI) and BrightAI ($97M, physical AI). Crunchbase also lists a $5B Isomorphic Labs round; no other reviewed source corroborates it (Crunchbase News).
FOLLOW THE EVIDENCE

The source trail.

Sources (10)
A LITTLE LESS NOISE. A LOT MORE CONTEXT.

Stay curious.
Follow the evidence.

Independent perspectives, the original sources, and room for the questions that don't have easy answers.

How we build the brief
Connect with us

Find us where you already read.